TECHNOLOGY - April 17, 1993
- Share via
From Times Staff and Wire Reports
Genentech Earnings Surge: Genentech Inc. said in San Francisco its earnings more than tripled in the first quarter on strong royalty payments and sales of its Protropin hormone and Activase heart drug. Net income rose to $14.3 million, or 12 cents a share, from $3.5 million, or 3 cents, a year earlier. The mean estimate of analysts surveyed by Zacks Investment Research was for earnings of 5 cents.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
